The Latest

  • Junk yard
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Avoiding the pharma ‘junk pile’ with launch readiness, pipeline rigor and ‘quick kills’

    Drug launches have underperformed expectations at a high rate, and pharmas need to get better at thinning the pipeline to make room for the real wins, says a life sciences consultant.

  • Brain scans of a person with Alzheimer's are seen in this conceptual image.
    Image attribution tooltip
    digicomphoto via Getty Images
    Image attribution tooltip

    The hunt for the brain’s biomarkers

    How Roche is finding better ways to diagnose brain conditions like Alzheimer’s and Parkinson’s disease.

  • Paxlovid
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip

    Pfizer’s Paxlovid flunks long COVID study as researchers uncover the condition’s deep toll

    While researchers gain ground understanding long COVID’s impact, viable treatments could still be a long way off.

  • A 3D illustration showing amyloid plaques in brain tissue
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    Lilly’s adcomm win shows amyloid and tau will likely dominate Alzheimer’s — for now

    Lilly is the latest to approach the coveted Alzheimer’s approval, but a slate of drugmakers are lining up clinical trials in amyloid and tau to take a shot at improving patient outcomes.

  • Close up of conference room with glasses of water on the table with papers, armchairs and a large window.
    Image attribution tooltip
    Igor Kutyaev via Getty Images
    Image attribution tooltip
    Making Moves

    Regenxbio CEO to step down after 15 years

    Kenneth Mills will become chair of the gene therapy developer's board while Curran Simpson, the current chief operating officer, will take his place as company head.

  • MDMA
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Despite adcomm rejection, Lykos CEO sees future for MDMA drug

    Although the rebuff makes approval “a bit more challenging,” Lykos is moving forward with the psychedelic-based treatment for PTSD.

  • digital blue pill on computer chip background
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Behind the powerful computations, AI’s role in pharma is still beset by challenges

    Small biotechs are saving time and money leveraging AI to develop new drugs, but incomplete data and disease complexity remain hurdles for the space.

  • Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    As Big Pharma places bigger bets on ADCs, here’s where the field is headed next

    With more drugmakers getting into the antibody-drug conjugate game, emerging innovations signal a bright future for the technology.

  • FDA headquarters with sign in foreground
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA’s platform designation aims to ease R&D pain points

    A new program creates approval pathways for multiple drugs developed on the same platform. 

  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Behind Big Pharma’s layoffs — is there an end in sight?

    A slew of major companies, including BMS, have announced cost-cutting measures in recent months. What will it take to turn the tide?

  • gambling chips
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma’s R&D gamble: picking pipeline winners in a risky field

    How leaders from biotech, Big Pharma and the investment world know when they've found the right candidate or company to back.

  • City of Hope Helford Clinical Research Hospital in Duarte, California
    Image attribution tooltip
    Permission granted by City of Hope
    Image attribution tooltip

    A ‘widening gap’ in access to new cancer meds drives efforts from City of Hope and Bristol Myers

    Cancer care is improving so quickly that receiving newer medications can be difficult — City of Hope’s wide oncology network and a 10-year commitment from Bristol Myers Squibb offer some solutions.

  • FibroBiologics CEO Pete O'Heeron at the opening bell for the Nasdaq
    Image attribution tooltip
    Permission granted by FibroBiologics
    Image attribution tooltip
    Biotech Spotlight

    Regenerative cell therapy biotech uses IPO to blast into human trials

    Bucking conventional fundraising, FibroBiologics’ CEO Pete O’Heeron explains why the biotech company bet on themselves in the public market.

  • A wall showing a Merck & Co. logo in Kenilworth, New Jersey
    Image attribution tooltip
    Courtesy of Merck & Co.
    Image attribution tooltip

    Merck and Moderna’s cancer vaccine snags a clinical win in a field decades old

    Cancer vaccines are taking off in the clinic, and a partnership between Merck and Moderna is at the forefront of a new wave of immunotherapy.

  • brand name drugs
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    What’s in a drug name? More than you might think.

    From regulatory restrictions to evocative letter strings, branded drug naming is both an art and a science. We break down the process.

  • Medicine capsules on blue racing lines
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A

    In an era of big patent losses, drug launches need years of runway

    Jim Lang, CEO of Eversana, explains the shifting commercial environment and how past drug launch failures are informing the future.

  • Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    After two Big Pharma deals, Nimbus looks to keep the hits coming

    With the billion-dollar-plus deals under its belt with Gilead and Takeda, the biotech’s CEO explains where the company is going next.

  • Symbolic of Sino-American relations, the flag of the United States of America and the flag of the Republic of China fly together on flag poles next to each other on a sunny, windy day.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Deadline looms for Chinese biotech contracts

    The latest version of The Biosecure Act working its way through Congress could make waves in the U.S. biotech industry.

  • Dave Kappos, former director, U.S. PTO
    Image attribution tooltip
    Permission granted by Cravath, Swaine & Moore
    Image attribution tooltip

    As Senate’s gaze lands on patents, a former US PTO chief calls the effort a ‘broad misunderstanding’

    To lower drug prices, lawmakers are turning to the drug patent system to outlaw some common practices — but a former patent agency director says it’s the wrong way to go.

  • 3d rendering of Antibody drug conjugates (ADCs) are targeted medicines that deliver chemotherapy agents to cancer cells
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Mythic Therapeutics aims to overcome one of ADC’s long-standing challenges

    By developing ADCs that bind more directly to the target, Mythic Therapeutics believes its technology could deliver a step change for efficacy and safety.

  • ftc federal trade commission
    Image attribution tooltip
    stock via Getty Images
    Image attribution tooltip

    FTC request may signal trouble for Novo/Catalent deal

    As Novo Nordisk aims to secure its manufacturing foothold for GLP-1s, regulators are digging for clues of anti-competitive behavior.

  • Robot arm DNA
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Can robots break the cell therapy bottleneck?

    A partnership between the cell therapy delivery specialist Portal Biotechnologies and precision robotics maker Multiply Labs could bring the manufacturing bottleneck under control, the CEOs said.

  • Abstract hand, falling can of pills, pills. Artwork or creative collage with art design
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    As weight loss booms, drugmakers look for an edge with oral options

    Supply of GLP-1 medications falls well short of demand, and oral versions of the drugs loom over Eli Lilly and Novo Nordisk’s dominance.  

  • two syringes
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Where competition is heating up in pharma

    The stage is set for potential blockbuster-level showdowns targeting these three indications.

  • A chromatic Pfizer sign hangs on a building façade
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    Pfizer and Lilly are elbowing into the direct-to-consumer market. Will it work?

    Direct-to-consumer platforms offer consumers an online path to sourcing popular medications, but some therapeutic areas may be better suited for the business model.